Benzene Ring Containing Patents (Class 514/576)
-
Patent number: 8575217Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.Type: GrantFiled: March 16, 2010Date of Patent: November 5, 2013Assignee: Genmedica Therapeutics SLInventors: Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Julio Cesar Castro Palomino Laria
-
Publication number: 20130287862Abstract: A microbicidal disinfecting composition and a method of preparing the same include the use of an acidifying agent that comprises at least one of an alkali metal bisulfate, ammonium bisulfate, or a combination thereof. The composition has broad-spectrum microbicidal properties and does not demonstrate cloudiness or precipitation when prepared, diluted, or otherwise exposed to hard water.Type: ApplicationFiled: June 28, 2013Publication date: October 31, 2013Inventor: John Alex Lopes
-
Patent number: 8569466Abstract: Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease.Type: GrantFiled: September 10, 2009Date of Patent: October 29, 2013Inventor: Nnochiri Ekwuribe
-
Publication number: 20130274230Abstract: The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.Type: ApplicationFiled: April 16, 2013Publication date: October 17, 2013Applicant: Allergan, Inc.Inventors: Richard L. Beard, Tien Duong, John E. Donello, Veena Viswanath, Michael E. Garst
-
Patent number: 8552062Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: September 27, 2006Date of Patent: October 8, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. von Borstel, Kirvin L. Hodge
-
Patent number: 8545816Abstract: Benzoic acid ester compounds of formula (I): wherein R and R1-R5 have the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscreens based on photochemical precursor properties of ultraviolet absorbers.Type: GrantFiled: March 20, 2006Date of Patent: October 1, 2013Assignee: Ferrer Internacional, S.A.Inventors: Ricardo Miralles, Santiago Nonell, Manuel M. Raga, Antonio Giuglietta, Jordi Teixidó
-
Patent number: 8530454Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.Type: GrantFiled: June 22, 2011Date of Patent: September 10, 2013Assignee: Amderma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Javier Angulo Frutos, Serafin Valverde Lopez, Atonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20130210828Abstract: The present disclosure provides novel poly(phenylene ethynylene) (PPE) compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various PPEs show antibacterial, antiviral and antifungal activity.Type: ApplicationFiled: July 13, 2011Publication date: August 15, 2013Inventors: David G. Whitten, Kirk S. Sehanze, Anand Parthsaray, Eunkyung Ji, Motokatsu Ogawa, Thomas S. Corbitt, Dimitri Dascier, Ying Wang, Linnea K. Ista
-
Publication number: 20130202580Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.Type: ApplicationFiled: February 14, 2013Publication date: August 8, 2013Applicant: AmDerma Pharmaceuticals, LLCInventor: AmDerma Pharmaceuticals, LLC
-
Publication number: 20130203851Abstract: Provided is the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, described is the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. Also described is the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, described is the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. Additionally, the therapeutic efficacy of said compounds, based on the combined anti proliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques is provided.Type: ApplicationFiled: February 21, 2013Publication date: August 8, 2013Applicant: AmDerma Pharmaceuticals, LLCInventor: AmDerma Pharmaceuticals, LLC
-
Patent number: 8492439Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: March 30, 2012Date of Patent: July 23, 2013Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 8492366Abstract: The solubility in solvent media, notably alcoholic media, of the beta-hydroxy acids (“BHAs”), notably the chemical skin peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one alpha-hydroxy acid (“AHA”); higher potency, more concentrated BHA skin peel products are thus formulated.Type: GrantFiled: February 26, 2003Date of Patent: July 23, 2013Assignee: Societe L'Oreal S.A.Inventors: Marc Cornell, Hani Fares, Sidney Peter Foltis, Isabelle Hansenne
-
Publication number: 20130184342Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.Type: ApplicationFiled: March 13, 2013Publication date: July 18, 2013Applicant: THE JACKSON LABORATORYInventor: THE JACKSON LABORATORY
-
Patent number: 8461207Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or selectin binding.Type: GrantFiled: February 23, 2011Date of Patent: June 11, 2013Assignee: Revotar Biopharmaceuticals AGInventors: Ewald Aydt, Remo Kranich
-
Patent number: 8450522Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: GrantFiled: March 4, 2009Date of Patent: May 28, 2013Assignee: Amgen Inc.Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
-
Patent number: 8435971Abstract: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques.Type: GrantFiled: June 27, 2011Date of Patent: May 7, 2013Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafin Valverde Lopez, Rosa Maria Lozano Puerto
-
Patent number: 8426369Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.Type: GrantFiled: December 7, 2007Date of Patent: April 23, 2013Assignee: Rutgers, The State University of New JerseyInventors: Agnes M. Rimando, Nanjoo Suh, Cassia Suemi Mizuno, Subhashini Reddy
-
Publication number: 20130072491Abstract: An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object is achieved by a composition that contains a compound represented by the following General Formula (I) or a salt thereof (refer to the Description for the definitions of the symbols used in the formula).Type: ApplicationFiled: August 31, 2012Publication date: March 21, 2013Applicant: Ajinomoto Co., Inc.Inventors: Reiko YASUDA, Yuzuru Eto, Yoshiro Kitahara
-
Publication number: 20130041037Abstract: Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.Type: ApplicationFiled: October 15, 2012Publication date: February 14, 2013Applicants: Alexandros Makriyannis, The United States of America as represented by the Secretary, Department of Health and Human ServiceInventors: George Kunos, Alexandros Makriyannis
-
Publication number: 20130029930Abstract: The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the Km of SIRT6 for a substrate, thereby increasing the deacetylase activity of SIRT6. The invention also provides compounds of the formulas (II) and (III).Type: ApplicationFiled: December 14, 2010Publication date: January 31, 2013Applicant: CORNELL UNIVERSITYInventors: Anthony Sauve, Ping Xu
-
Patent number: 8343934Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: GrantFiled: June 30, 2010Date of Patent: January 1, 2013Assignee: University of MemphisInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Elton Jeffrey North
-
Publication number: 20120328541Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Inventors: Werner Baschong, Oliver Reich, Sébastien Mongiat
-
Patent number: 8334328Abstract: The main goal of the present invention is the development of a polymerizable material for isolation and protection of the gums and generally the soft tissues of the oral cavity. For better protection during various procedures of the dental surfaces. The composition of the material can contain many other substances that strengthen its qualities and protective action. Such substances can be various substances that have antioxidative, sedative, anti-inflammatory, analgesic, anti-irritant action etc.Type: GrantFiled: February 9, 2007Date of Patent: December 18, 2012Assignee: KLOX Technologies Inc.Inventors: Vassilios Marmarinos, Paschalis Paschalakis
-
Publication number: 20120264708Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by modulating the action of the P2X7 and/or P2Y12 receptors of the RPE cells, specifically decreasing the acidity (pHL) of the RPE lysosomes by administering selected receptor antagonists affecting the action of the P2X7 and/or P2Y12 receptors of the RPE. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.Type: ApplicationFiled: April 27, 2012Publication date: October 18, 2012Inventors: Claire Mitchell, Alan Laties
-
Publication number: 20120251629Abstract: The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1? inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.Type: ApplicationFiled: October 8, 2010Publication date: October 4, 2012Applicant: UNIVERSITY OF ROCHESTERInventor: Marc Halterman
-
Patent number: 8278356Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or selectin binding.Type: GrantFiled: February 23, 2011Date of Patent: October 2, 2012Assignee: Revotar Biopharmaceuticals AGInventors: Ewald Aydt, Remo Kranich
-
Publication number: 20120234721Abstract: The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided.Type: ApplicationFiled: September 9, 2011Publication date: September 20, 2012Applicant: Neurotherapeutics Pharma, Inc.Inventors: Daryl W. HOCHMAN, John J. Partridge
-
Publication number: 20120232153Abstract: Methods and compositions for biofilm remediation are disclosed. Biofilm is reduced and removed from soiled surfaces by providing to a surface in need an effective amount of a composition comprising a biocidal surfactant and at least one organic solvent. According to the invention, the biofilm remediation compositions reduce and remove biofilm formation by administering a one-step cleaner and disinfectant. The biofilm remediation compositions are stable and effective in concentrated and diluted ready-to-use formulations comprising an anionic sulfated or sulfonated surfactant that is not an organocarboxylic acid, a sparingly soluble organic solvent and optionally a soluble organic solvent.Type: ApplicationFiled: March 11, 2011Publication date: September 13, 2012Applicant: ECOLAB USA INC.Inventors: GREGORY G. GRIESE, MARK LEVITT, RICHARD STAUB, STEFANIE GILBRETH
-
Publication number: 20120232154Abstract: Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Applicant: LANXESS DEUTSCHLAND GMBHInventors: Johannes KAULEN, Erasmus VOGL, Edwin RITZER, Manfred HOFFMANN
-
Publication number: 20120225848Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a GABAB antagonist, or a blocker of Kir3.2 potassium channels, is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.Type: ApplicationFiled: September 17, 2010Publication date: September 6, 2012Inventors: Alexander M. Kleschevnikov, William C. Mobley
-
Patent number: 8257478Abstract: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2,5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.Type: GrantFiled: December 16, 2005Date of Patent: September 4, 2012Assignee: The Hong Kong University of Science and TechnologyInventors: Pei-Yuan Qian, Xiancui Li, Fuk Ning Kwong, Lai Hung Yang, Sergey Vladimirovich Dobretsov
-
Publication number: 20120214769Abstract: The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 8, 2011Publication date: August 23, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Jorge E. Gomez-Galeno, K. Raja Reddy, Paul D. van Poelje, Robert Huerta Lemus, Thanh Huu Nguyen, Matthew P. Grote, Qun Dang, Scott J. Hecker, Venkat Reddy Mali, Mingwei Chen, Zhili Sun, Serge Henri Boyer, Haiqing Li, William Craigo
-
Patent number: 8232319Abstract: To provide an amino phosphate derivative having an excellent sphingosine-1-phosphate (S1P) receptor modulatory action. As a result of continued intensive research to create a highly safe compound which has an S1P receptor modulatory action, is has been discovered that an amino phosphate derivative represented by the following general formula (1), has a strong S1P receptor modulatory action.Type: GrantFiled: August 7, 2007Date of Patent: July 31, 2012Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yasushi Kohno, Kiyoshi Fujii, Tatsuhiro Saito
-
Patent number: 8227515Abstract: Method of treating a tumor in a patient in need thereof by administering to the patient an effective amount of 4-[6-(diethylaminomethyl)naphth-2-ylmethyloxycarbamoyl]benzohydrozamic acid.Type: GrantFiled: December 10, 2003Date of Patent: July 24, 2012Assignee: Italfarmaco S.p.A.Inventors: Flavio Leoni, Paolo Mascagni
-
Publication number: 20120178747Abstract: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm.Type: ApplicationFiled: November 14, 2006Publication date: July 12, 2012Inventors: Dianqing (Dan) Wu, Dakai Liu, James J. Donegan
-
Publication number: 20120172435Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.Type: ApplicationFiled: August 24, 2010Publication date: July 5, 2012Inventors: Richard Dana Kopke, Robert A. Floyd
-
Publication number: 20120172340Abstract: Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided.Type: ApplicationFiled: October 7, 2010Publication date: July 5, 2012Applicant: BIOMOL International L.P.Inventors: Konrad T. Howitz, Robert E. Zipkin
-
Publication number: 20120142780Abstract: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques.Type: ApplicationFiled: June 27, 2011Publication date: June 7, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafín Valverde Lopez, Rosa María Lozano Puerto
-
Publication number: 20120136061Abstract: A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural killer (NK) cells is elevated. Specifically, the composition comprises lycopene and resveratrol in the range of 1:10 to 10:1 by molar; more preferably 1:1 to 3:1 by molar, and most preferably at 3:1. Alternatively, the preferred ratio may be expressed as 1:4 to 25:1 by weight; more preferably 2½:1 to 7½:1 by weight, and most preferably at 7½:1. The composition may be formulated for oral intake as a pharmaceutical, dietary supplement or food product and provided in therapeutically effective amounts to a mammal, preferably in a dosage of about 3.5 mg per day per 20 g of a mammalian body mass in a ratio of 2½:1 by weight, which can be translated to about 400 mg to 1000 mg per day for a typical human in need of elevating NK cell activity.Type: ApplicationFiled: April 13, 2010Publication date: May 31, 2012Applicant: HSIEHS BIOTECH (SINGAPORE) PTE LTDInventor: Kun Lung Hsieh
-
Patent number: 8173706Abstract: Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: April 2, 2010Date of Patent: May 8, 2012Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Publication number: 20120108551Abstract: The present invention relates to compositions that may alleviate symptoms of ocular stress, as well as methods of their production, use, and storage compositions. The compositions comprise at least one ocular epithelial cell associating group and at least one hydrophilic group. In one embodiment the at least one ocular epithelial cell associating group and at least one hydrophilic group are substituents on a conjugated polyaromatic core. The compositions may be used in ophthalmic compositions and ophthalmic devices.Type: ApplicationFiled: October 29, 2010Publication date: May 3, 2012Inventors: Frank F. Molock, JR., John C. Heaton
-
Publication number: 20120087904Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20120077785Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.Type: ApplicationFiled: September 13, 2011Publication date: March 29, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sanchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafín Valverde Lopez, Rosa María Lozano Puerto
-
Patent number: 8129361Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.Type: GrantFiled: June 13, 2008Date of Patent: March 6, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara
-
Publication number: 20120046364Abstract: The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.Type: ApplicationFiled: February 9, 2010Publication date: February 23, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Serge H. Boyer, Scott J. Hecker, Mali Venkat Reddy
-
Publication number: 20120022024Abstract: This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.Type: ApplicationFiled: July 21, 2011Publication date: January 26, 2012Applicant: The Board of Trustees of the University of IllinoisInventors: Eric Oldfield, Yongcheng Song
-
Publication number: 20120015912Abstract: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.Type: ApplicationFiled: January 7, 2011Publication date: January 19, 2012Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Maria Luisa Krauel, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
-
Patent number: 8097651Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.Type: GrantFiled: January 7, 2010Date of Patent: January 17, 2012Assignee: APR Applied Pharma Research s.a.Inventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
-
Patent number: 8097267Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.Type: GrantFiled: September 9, 2009Date of Patent: January 17, 2012Assignee: APR Applied Pharma Research s.a.Inventors: Giorgio Reiner, Alberto Reiner
-
Publication number: 20120004225Abstract: The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl? co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.Type: ApplicationFiled: January 22, 2010Publication date: January 5, 2012Applicant: NeuroTherapeutics Pharma, Inc.Inventors: Stephen Wanaski, John J. Partridge, Stephen D. Collins